Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

@article{Moros2014SynergisticAA,
  title={Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma},
  author={Alexandra Moros and Varenka Rodriguez and Ifig{\`e}nia Saborit-Villarroya and Arnau Montraveta and Patricia Balsas and P Sandy and Antonio Olivas Martinez and Adrian Wiestner and Emmanuel Normant and El{\'i}as Campo and Patricia P{\'e}rez-Gal{\'a}n and Dolors Colomer and Ga{\"e}l Rou{\'e}},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={2049-2059}
}
Bortezomib therapy has shown promising clinical activity in mantle cell lymphoma (MCL), but the development of resistance to proteasome inhibition may limit its efficacy. To unravel the factors involved in the acquisition of bortezomib resistance in vivo, immunodeficient mice were engrafted with a set of MCL cell lines with different levels of sensitivity to the drug, followed by gene expression profiling of the tumors and functional validation of the identified gene signatures. We observed an… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
25 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…